News

ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment

webinar

Videos and audiocasts

ValiRx Q&A Live Webinar Held on 13th December 2022

webinar

ValiRx to host live Q&A shareholder webinar

Suzy Presenting at BOS Manchester 2022

ValiRx attends Biotech Outsourcing Strategies 2022

Suzanne Dilly

ValiRx CEO introduces Cytolytix at London South East webinar

Videos and audiocasts

LSE Investor Presentation Introducing Cytolytix

Mark Treharne and Cathy Tralau-Stewart at Bio-Europe

ValiRx attends Bio-Europe 2022

Suzanne Dilly - CEO ValiRx

ValiRx signs IP license agreement with King's College London to progress triple negative breast cancer treatment

Stella Panu - Proposed Non-Executive Director, Valirx plc

ValiRx appoints NED to support growth and investment drive

Suzanne Dilly - CEO ValiRx

Ada Lovelace Day 2022: In conversation with ValiRx’s CEO

Videos and audiocasts

ValiRx Q&A Live Webinar Held on 29th September 2022

ValiRx CSO

ValiRx bolsters drug discovery expertise with key appointment

Videos and audiocasts

Successful evaluation of triple negative breast cancer programme

Events and presentations

AGM & Live Q&A with Presentation Held on 30th June 2022